<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012099</url>
  </required_header>
  <id_info>
    <org_study_id>HG-BMT-PIIa-01</org_study_id>
    <nct_id>NCT04012099</nct_id>
  </id_info>
  <brief_title>the Hypertrophic Scar Prevention of BMT101.</brief_title>
  <official_title>An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of BMT 101 Administration for the Prevention of Hypertrophic Scar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase
      2a Therapeutic Exploratory Clinical Trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a comparative evaluation between the control group (untreated-control) and the study group
      (treatment) within a subject, it was decided to assign ten subjects to each of the three dose
      groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reducing the hypertrophic scar after scar revision surgery</measure>
    <time_frame>Week 2, 6, 10, 22</time_frame>
    <description>to evaluate Differences in Visual Analogue Scale (VAS) score between the study group and the control group when independent evaluators assessed the severity of the hypertrophic scars.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation of BMT101</measure>
    <time_frame>Week 2, 6, 10, 22</time_frame>
    <description>To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective revision of a hypertrophic scar</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertrophic Scar</condition>
  <arm_group>
    <arm_group_label>BMT101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMT101 injection (treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Un-treated control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMT101</intervention_name>
    <description>Intradermal injection to each of 3 dose-groups.</description>
    <arm_group_label>BMT101</arm_group_label>
    <other_name>cp-asiRNA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female adults aged 19-55 years

          -  Those who plan to undergo a revision surgery to remove hypertrophic scar resulted from
             a previous abdominal surgery

          -  Those who voluntarily signed the written consent and agreed to participate in the
             study.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Those with clinically significant systemic disease (e.g. diabetes, hematologic
             disease, allergic or immunogenic systemic skin disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinhong park</last_name>
    <phone>+82-2-6966-1651</phone>
    <email>jhpark@hugel.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hugel</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Korea</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scar prevention</keyword>
  <keyword>siRNA</keyword>
  <keyword>scar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cicatrix, Hypertrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

